Fewer generics rush to enter market after linagliptin's patent expiry

[ad_1]

When Sitagliptin went off patent, nearly 200 brands were vying for a share of the market

[ad_2]

Source link

Table of Contents

Indian fintech payment firms have no data advantage over banks: Moody's